EGFR and non-small cell lung carcinoma: This contrasts the results of several previous investigations including all-comer and/or non-TKI-treated NSCLC cohorts [(24) and (25) both published in 2019, but analyzing patients diagnosed until 2012 and 2013, respectively; (26) analyzing EGFR+ patients diagnosed until 2011], which have observed a slight, but significant OS advantage in the “secondary” setting.